Abstract
Rheumatoid Arthritis (RA) is the most common chronic inflammatory disease of the joints and is characterized by a complex genetic architecture. In recent years, a substantial advance has been performed in the identification of the genes that increase the risk to develop RA. Genome-Wide Association Studies (GWAS) have allowed the characterization of more than 40 new susceptibility genes and the confirmation of a marked differential genetic background between patients expressing anti-cyclic citrullinated peptide antibodies (ACPA, approximately 80% of all RA patients) and ACPA negative RA patients. GWAS have also confirmed the existence of a common genetic basis between RA and other autoimmune diseases and the overrepresentation of specific biological pathways like antigen presentation and TNF signaling. Dense genotyping analysis has also allowed the detailed characterization of the different association signals within the HLA region, the strongest risk locus for RA. In the present manuscript, we also review the most recent advances in the genetics of clinically relevant subphenotypes in RA which are the response to treatment and the severity of the disease. In the next years the increasing ability to characterize the DNA variation and the availability of well characterized patient cohorts will be critical to translate genetic information into the much awaited personalized medicine in RA.
Keywords: ACPA, Disease severity, Genetics, Risk, GWAS, HLA, Pharmacogenetics, Rheumatoid Arthritis.
Current Topics in Medicinal Chemistry
Title:The Genetic Architecture of Rheumatoid Arthritis: From Susceptibility to Clinical Subphenotype Associations
Volume: 13 Issue: 6
Author(s): Antonio Julia and Sara Marsal
Affiliation:
Keywords: ACPA, Disease severity, Genetics, Risk, GWAS, HLA, Pharmacogenetics, Rheumatoid Arthritis.
Abstract: Rheumatoid Arthritis (RA) is the most common chronic inflammatory disease of the joints and is characterized by a complex genetic architecture. In recent years, a substantial advance has been performed in the identification of the genes that increase the risk to develop RA. Genome-Wide Association Studies (GWAS) have allowed the characterization of more than 40 new susceptibility genes and the confirmation of a marked differential genetic background between patients expressing anti-cyclic citrullinated peptide antibodies (ACPA, approximately 80% of all RA patients) and ACPA negative RA patients. GWAS have also confirmed the existence of a common genetic basis between RA and other autoimmune diseases and the overrepresentation of specific biological pathways like antigen presentation and TNF signaling. Dense genotyping analysis has also allowed the detailed characterization of the different association signals within the HLA region, the strongest risk locus for RA. In the present manuscript, we also review the most recent advances in the genetics of clinically relevant subphenotypes in RA which are the response to treatment and the severity of the disease. In the next years the increasing ability to characterize the DNA variation and the availability of well characterized patient cohorts will be critical to translate genetic information into the much awaited personalized medicine in RA.
Export Options
About this article
Cite this article as:
Julia Antonio and Marsal Sara, The Genetic Architecture of Rheumatoid Arthritis: From Susceptibility to Clinical Subphenotype Associations, Current Topics in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/1568026611313060005
DOI https://dx.doi.org/10.2174/1568026611313060005 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Nanomaterial Based Affinity Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry for Biomolecules and Pathogenic Bacteria
Recent Patents on Nanotechnology Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B
Current Genomics Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Discovery of Selective Small Molecular TACE Inhibitors for the Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry In Vitro Analysis of Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis as a Possible Predictable Marker of TNF-alpha Blockers
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
Drug Metabolism Letters The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Low Level Laser Therapy [LLLT] in Inflammatory and Rheumatic Diseases:A Review of Therapeutic Mechanisms
Current Rheumatology Reviews Comparison of <i>In Vitro</i> and <i>In Vivo</i> Effects of Infliximab on Cytokine Production in Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology